BioSpace News Archive

CN Bio, a leading provider of single- and multi-organ microphysiological systems, announced it has raised a $21 million investment in the first close of its Series B fundraising round.

ProQR Therapeutics NV. announced the Annual General Meeting of Shareholders will take place on Wednesday, May 22, 2024 at 1630 CET at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands.

Tiziana Life Sciences, Ltd. announced that the U.S. Food and Drug Administration has allowed its intranasal foralumab non-active Secondary Progressive Multiple Sclerosis Expanded Access Program to expand from 10 patients to a total of 30 patients.

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.

Calidi Biotherapeutics Inc. is pleased to invite investors to a webinar on April 24, 2024 at 4:15 p.m. ET.

Lisata Therapeutics, Inc. announced that the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1 (also known as “CEND-1”), Lisata’s lead product candidate, in combination with standard-of-care (“SoC”) chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (“mPDAC”).

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution.

Agenus Inc. today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Tharimmune, Inc. announced today an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced the appointment of Ajay Nirula, M.D., Ph.D., as the company’s executive vice president and head of research and development, and the addition of Adrian S. Ray, Ph.D., to its scientific advisory board.